• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

PCOS during the menopausal transition and after menopause: a systematic review and meta-analysis
Hum Reprod Update. 2023 Jun 23:dmad015. doi: 10.1093/humupd/dmad015. Online ahead of print.ABSTRACTBACKGROUND: Current knowledge about the consequences of PCOS during the late reproductive years and after menopause is limited.OBJECTIVE AND RATIONALE: We performed a systematic review and meta-analysis of data on the pathophysiology, clinical manifestations, diagnosis, prognosis, and treatment of women ≥45 years of age-peri- or postmenopausal-with PCOS.SEARCH METHODS: Studies published up to 15 April 2023, identified by Entrez-PubMed, EMBASE, and Scopus online facilities, were considered. We included cross-sectional or pro...
Source: Cancer Control - June 24, 2023 Category: Cancer & Oncology Authors: Mercedes Mill án-de-Meer Manuel Luque-Ram írez L ía Nattero-Chávez H éctor F Escobar-Morreale Source Type: research

Causes and Consequences of Polycystic Ovary Syndrome: Insights from Mendelian Randomization
CONCLUSIONS: The accumulation of genome-wide association studies in PCOS has enabled multiple MR analyses identifying factors that may cause PCOS or be caused by PCOS. This knowledge will be critical to future development of measures to prevent PCOS in girls at risk as well as prevent complications in those who have PCOS.PMID:34669940 | DOI:10.1210/clinem/dgab757
Source: Clinical Genitourinary Cancer - October 20, 2021 Category: Cancer & Oncology Authors: Tiantian Zhu Mark O Goodarzi Source Type: research

NAMPT as a Dedifferentiation-Inducer Gene: NAD+ as Core Axis for Glioma Cancer Stem-Like Cells Maintenance
Conclusion and Perspectives Gliomas are the most prevalent primary brain cancer in adults and include a broad category of tumors including astrocytoma, oligodendroglioma, and GBM. Regardless of tumor aggressiveness, malignancy, and infiltration, these glia-derived tumors rarely exceed a median survival time of 12–14 months. Driven by the infiltrative nature of these tumors, the clinical approach is difficult and relapses often occur with fatal consequences. These unsuccessful attempts to control glioma's fate have fostered research looking for more effective therapies. (GSCs) are a small subset of CD133&#...
Source: Frontiers in Oncology - May 2, 2019 Category: Cancer & Oncology Source Type: research